Grant of Options

RNS Number : 7598L

Byotrol PLC

31 December 2018

 

31 December 2018

Byotrol plc

("Byotrol", the "Group" or the "Company")

GRANT OF OPTIONS

Byotrol plc, the AIM listed anti-microbial technology company, announces that on 28 December 2018 it granted a total of 3,000,000 options over the Company's ordinary shares of 0.25 pence each ("Options" and "Ordinary Shares" respectively) under the Company's existing Enterprise Management Incentive Scheme to a PDMR and to an employee of the Company.

Some of the Options are being granted to a PDMR of the Company ("PDMR Options") and are detailed below:

	Position	No. of New Options Granted	No. of Options held post grant	Shareholding in existing Ordinary Shares in the Company
Richard Hayman	MD, Medimark Scientific Ltd	2,000,000	2,000,000	8,080,235
	(PDMR)

The Options, all of which are exercisable at 2 pence per Ordinary Share over a five year period, vest on varying dates and vest in 5 tranches subject to certain share price performance targets and other performance metrics. The Options expire on 28 June 2024.

Following the grant of the 3,000,000 Options, there will be 39,248,250 Options in issue representing 9.1% per cent. of the Company's issued share capital.

Enquiries:

Byotrol plc                                                                                                          01925 742 000

David Traynor - Chief Executive

finnCap Ltd                                                                                                       020 7220 0500

Geoff Nash / Kate Bannatyne - Corporate Finance

Richard Chambers - ECM

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

Notes to Editors:

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

Our patented suite of technologies deliver powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.

Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.

For more information, please go to www.byotrol.co.uk

Accordingly, the Company makes the following notification in accordance with the EU Market Abuse Regulation (No 596/2014):

	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Richard Hayman
	Reason for the Notification
a)	Position/status	MD, Medimark Scientific Limited
b)	Initial notification/Amendment	Initial
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Byotrol Plc
b)	LEI	213800AJMTSTIPA59A34
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument Identification code	ordinary shares of 0.25p each ("Ordinary Shares") GB00B0999995
b)	Nature of the transaction	Award of Options over Ordinary Shares
c)	Price(s) and volume(s)	Volume - 2,000,000 Exercise Price - 2 pence
d)	Aggregated information:	See 4c) above
e)	Date of the transaction	28 December 2018
f)	Place of the transaction	Outside of a trading venue

 

END

 

 

DSHPGGPCPUPRGAR